Journal
EXPERT REVIEW OF CARDIOVASCULAR THERAPY
Volume 8, Issue 8, Pages 1069-1077Publisher
TAYLOR & FRANCIS INC
DOI: 10.1586/ERC.10.90
Keywords
acute coronary syndrome; antiplatelet therapy; cangrelor; P2Y(12)-receptor antagonist; platelet
Categories
Funding
- Honoraria/lectures: Bristol Myers Squibb
- SanofiAventis
- Eli Lilly and Company
- Daiichi Sankyo, Inc. Honoraria/advisory board: Bristol Myers Squibb
- Astra Zeneca
- Portola Pharmaceuticals
- Novartis
- Arena Pharmaceuticals
- GlaxoSmithKline
- Otsuka
- Accumetrics
- Medicines Company
- AstraZeneca
- Eisai
- Portola Pharmaceutical
- Schering-Plough
- Johnson and Johnson
Ask authors/readers for more resources
Antiplatelet drugs represent the cornerstone of treatment for cardiovascular atherothrombotic disease. Dual oral antiplatelet therapy with aspirin and oral ADP-receptor antagonists, such as clopidogrel, has been the standard choice for prevention of ischemic events in patients with acute coronary syndrome and in those undergoing percutaneous coronary intervention. However, due to the limitations of clopidogrel, such as interindividual-response variability, drug-drug interactions, slow onset of action and irreversible inhibitory effects, novel antiplatelet agents are under clinical development. Cangrelor is a reversible, potent, competitive inhibitor of the ADP P2Y 12 receptor that is administered intravenously and rapidly achieves near complete inhibition of ADP-induced platelet aggregation. These pharmacological properties make cangrelor a promising drug for clinical use. However, recent large-scale Phase III clinical investigations failed to show significant clinical benefit on the primary end point with cangrelor. This article provides an overview of the current status of knowledge on cangrelor, focusing on its pharmacologic properties and clinical development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available